ROCKVILLE, Md., Feb. 19 /PRNewswire/ -- Pinnacle Biologics, a private, full-service pharmaceutical and biotech solutions company, today announced it has entered into an exclusive distribution agreement with MedImmune for Ethyol(R) (amifostine). The agreement, which is scheduled to take effect on June 1, 2008, grants Pinnacle Biologics exclusive Ethyol marketing authorization, certain licenses and distribution rights in Western Europe, Turkey and Israel. Additional terms of the agreement were not disclosed.
“The agreement with MedImmune represents the first step in Pinnacle’s growth as well as provides the opportunity to showcase our vast capability to assist large pharmaceutical and biotechnology companies in optimizing the international market potential of mature products without diversion of resources from core businesses,” said Guillermo Herrera, chairman of the board of Pinnacle Biologics. “Our extensive international industry experience and knowledge will potentially allow MedImmune to maximize the revenue potential of Ethyol in Europe.”
About Pinnacle Biologics
Founded in 2007 by health care executives Guillermo Herrera, James Miller, and Viren Grover, Pinnacle Biologics is a premier international company that excels in assisting pharmaceutical and biotech companies that require a total solution in either launching products or maximizing/monetizing the value of products late in their life cycle. Pinnacle forms exclusive relationships with research-based pharmaceutical multi-national corporations and biotechnology companies to take products to the next level.
Pinnacle provides a full range of services including regulatory, sales, marketing, distribution (including billing and collections), pharmacovigilence, product safety, market research and administrative services.
CONTACT: Company, James R. Miller, President & CEO of Pinnacle,
+1-240-372-4599; or Media, Geoff Curtis of WeissComm Partners,
+1-312-284-4701, for Pinnacle Biologics
